Indie Asset Partners LLC Acquires 126 Shares of Novo Nordisk A/S (NYSE:NVO)

Indie Asset Partners LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,128 shares of the company’s stock after purchasing an additional 126 shares during the period. Indie Asset Partners LLC’s holdings in Novo Nordisk A/S were worth $269,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dividend Assets Capital LLC grew its holdings in shares of Novo Nordisk A/S by 3.1% in the fourth quarter. Dividend Assets Capital LLC now owns 214,615 shares of the company’s stock worth $18,461,000 after acquiring an additional 6,395 shares during the period. Outfitter Financial LLC lifted its position in shares of Novo Nordisk A/S by 9.9% in the fourth quarter. Outfitter Financial LLC now owns 8,795 shares of the company’s stock valued at $757,000 after acquiring an additional 795 shares in the last quarter. Bank of Stockton lifted its position in shares of Novo Nordisk A/S by 6.5% in the fourth quarter. Bank of Stockton now owns 8,151 shares of the company’s stock valued at $701,000 after acquiring an additional 499 shares in the last quarter. Arcadia Investment Management Corp MI lifted its position in shares of Novo Nordisk A/S by 29.8% in the fourth quarter. Arcadia Investment Management Corp MI now owns 4,354 shares of the company’s stock worth $375,000 after buying an additional 1,000 shares in the last quarter. Finally, Centricity Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $178,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 5.2 %

NVO opened at $88.07 on Friday. The stock has a market cap of $395.19 billion, a price-to-earnings ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The stock’s 50 day moving average price is $86.01 and its 200-day moving average price is $108.22. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NVO shares. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.